Altamira Therapeutics Ltd. (CYTO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now
Auris (CYTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Altamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call Transcript
Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q2 2024 Results Conference Call September 24, 2024 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman & Chief Executive Officer Covadonga Paneda - Chief Operating Officer Conference Call Participants Hunter Diamond - Diamond Equity Operator Good morning, and welcome to the Altamira Therapeutics First Half 2024 and Business Update Conference Call.
Altamira Therapeutics Ltd. (CYTO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Altamira Therapeutics Ltd. ever had a stock split?
Altamira Therapeutics Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Thomas Meyer CEO | NASDAQ (CM) Exchange | G0360L100 CUSIP |
| BM Country | 10 Employees | - Last Dividend | 13 Dec 2023 Last Split | - IPO Date |
Overview
Altamira Therapeutics Ltd. emerges as a trailblazing entity within the biopharmaceutical landscape, primarily focusing its operations in Switzerland and Australia. This company distinguishes itself through its dedication to preclinical-stage research and development, particularly in the realm of innovative peptide-based nanoparticle technologies aimed at the efficacious delivery of ribonucleic acid (RNA) to extrahepatic tissues. Initially established in 2003 and previously recognized as Auris Medical Holding Ltd., the organization underwent a significant rebranding in July 2021 to Altamira Therapeutics Ltd. Its strategic headquarters are located in Hamilton, Bermuda, embodying a testament to the company's evolving journey and commitment to medical advancements in the therapeutic domain.
Products and Services
- Bentrio: Altamira offers Bentrio, a pioneering drug-free nasal spray uniquely formulated to provide a shield against airborne viruses and allergens. This innovative solution stands out for its non-pharmacological approach, catering to the growing demand for preventive healthcare measures in the face of evolving environmental challenges.
- OligoPhore/SemaPhore Platforms: At the core of Altamira's technological prowess are the OligoPhore and SemaPhore platforms. These cutting-edge peptide-based nanoparticle technologies are strategically designed for the targeted delivery of ribonucleic acid (RNA) to extrahepatic tissues, marking a significant leap forward in the treatment of various medical conditions.
- AM-401: The company is in the development phase of AM-401, a promising treatment candidate tailored for combating KRAS driven cancers. This initiative underscores Altamira's commitment to addressing critical needs within the oncology sector.
- AM-411: Targeting autoimmune disorders, AM-411 represents Altamira's focused endeavor to develop a therapeutic solution for rheumatoid arthritis, a prevalent condition affecting millions worldwide.
- AM-125: Currently in phase II clinical trial, AM-125 is being explored as a potential intranasal treatment for vertigo. This reflects the company's innovative approach towards addressing neurological disorders with novel delivery systems.
- Keyzilen: Altamira's Keyzilen is undergoing phase II/III clinical trials, aiming to offer a breakthrough treatment for acute inner ear tinnitus. The development of this drug epitomizes the firm's dedication to pioneering solutions for auditory conditions.
- Sonsuvi: In the critical phase III of clinical development, Sonsuvi is engineered as a therapeutic measure for acute inner ear hearing loss, reinforcing Altamira's focus on advancing treatments for hearing impairments.
